At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone
In Brief
A clinical study evaluating Aprepitant 0mg, Aprepitant 40mg, and 7 other interventions for Narcotic Abuse. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.
Study Details
Timeline
Interventions
Aprepitant 0mg, p.o. pretreatment
Aprepitant 40mg, p.o. pretreatment
Aprepitant 200mg, p.o. pretreatment
Oxycodone 0mg, p.o.
Oxycodone 20mg, p.o.
Oxycodone 40mg, p.o.
Oxycodone 0mg, IN
Oxycodone 15mg, IN
Oxycodone 30mg, IN